| Literature DB >> 33494095 |
Bryan A Johnson1, Xuping Xie2, Adam L Bailey3, Birte Kalveram4, Kumari G Lokugamage1, Antonio Muruato1, Jing Zou2, Xianwen Zhang2, Terry Juelich4, Jennifer K Smith4, Lihong Zhang4, Nathen Bopp4, Craig Schindewolf1, Michelle Vu1, Abigail Vanderheiden5,6, Emma S Winkler3,7, Daniele Swetnam2, Jessica A Plante1, Patricia Aguilar4, Kenneth S Plante1, Vsevolod Popov4, Benhur Lee8, Scott C Weaver1,9, Mehul S Suthar5,6,10, Andrew L Routh2, Ping Ren4, Zhiqiang Ku11, Zhiqiang An11, Kari Debbink12, Michael S Diamond3,7,13, Pei-Yong Shi2,9, Alexander N Freiberg4,9, Vineet D Menachery14,15.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-a new coronavirus that has led to a worldwide pandemic1-has a furin cleavage site (PRRAR) in its spike protein that is absent in other group-2B coronaviruses2. To explore whether the furin cleavage site contributes to infection and pathogenesis in this virus, we generated a mutant SARS-CoV-2 that lacks the furin cleavage site (ΔPRRA). Here we report that replicates of ΔPRRA SARS-CoV-2 had faster kinetics, improved fitness in Vero E6 cells and reduced spike protein processing, as compared to parental SARS-CoV-2. However, the ΔPRRA mutant had reduced replication in a human respiratory cell line and was attenuated in both hamster and K18-hACE2 transgenic mouse models of SARS-CoV-2 pathogenesis. Despite reduced disease, the ΔPRRA mutant conferred protection against rechallenge with the parental SARS-CoV-2. Importantly, the neutralization values of sera from patients with coronavirus disease 2019 (COVID-19) and monoclonal antibodies against the receptor-binding domain of SARS-CoV-2 were lower against the ΔPRRA mutant than against parental SARS-CoV-2, probably owing to an increased ratio of particles to plaque-forming units in infections with the former. Together, our results demonstrate a critical role for the furin cleavage site in infection with SARS-CoV-2 and highlight the importance of this site for evaluating the neutralization activities of antibodies.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33494095 PMCID: PMC8175039 DOI: 10.1038/s41586-021-03237-4
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962